travoprost + timolol




Firma Chun Cheong
Concise Prescribing Info
Travoprost 40 mcg/mL, timolol (as maleate) 5 mg/mL
Decrease of IOP in adult patients w/ open-angle glaucoma or ocular HTN who are insufficiently responsive to topical β-blockers or prostaglandin analogues.
Dosage/Direction for Use
Adult including the elderly 1 drop in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. Administer at the same time each day.
Hypersensitivity to travoprost, timolol or to other β-blockers. Reactive airway disease including bronchial asthma, or a history of bronchial asthma, severe COPD. Sinus bradycardia, sick sinus syndrome, including sino-atrial block, 2nd or 3rd degree AV block not controlled w/ pace-maker. Overt cardiac failure or cardiogenic shock. Severe allergic rhinitis, corneal dystrophies.
Special Precautions
Patients w/ CV diseases & hypotension; severe peripheral circulatory disturbance/disorders; mild/moderate COPD. Resp reactions in patients w/ asthma. Patients subject to spontaneous hypoglycaemia or patients w/ labile diabetes. May potentiate muscle weakness consistent w/ certain myasthenic symptoms. May induce dryness of eyes. Choroidal detachment. Patients already receiving a systemic β-blocking medicinal product. May block systemic β-agonist effects eg, of adrenaline. May mask the signs of hyperthyroidism. Patients w/ history of atopy or severe anaphylactic reaction to a variety of allergens. Use of 2 local prostaglandins is not recommended. Ocular effects eg, gradual change in the eye colour, periorbital & lid changes, change in eyelashes, slight enlargement of the palpebral fissure. Aphakic patients, pseudophakic patients w/ a torn posterior lens capsule or anterior chamber lenses, or patients w/ known risk factors for cystoid macular oedema; patients w/ known predisposing risk factors for iritis/uveitis, & in patients w/ active intraocular inflammation. Contains propylene glycol & polyoxyethylene hydrogenated castor oil 40. Remove contact lenses prior to application & wait 15 min after instillation of the dose before reinsertion. If blurred vision occurs at instillation, wait until the vision clears before driving or using machines. Must not be used in women of childbearing potential unless adequate contraceptive measures are in place. Pregnant women or women attempting to become pregnant should avoid direct exposure to the contents of DuoTrav. Should not be used during pregnancy unless clearly necessary. Not recommended in breastfeeding women.
Adverse Reactions
Ocular hyperaemia. Punctate keratitis, eye pain, visual disturbance, vision blurred, dry eye, eye pruritus, ocular discomfort, eye irritation.
Drug Interactions
Potential for additive effects resulting in hypotension &/or marked bradycardia w/ oral Ca-channel blockers, β-adrenergic blocking agents, antiarrhythmics, digitalis glycosides, parasympathomimetics, guanethidine. Potentiated hypertensive reaction to sudden w/drawal of clonidine. Potentiated systemic β-blockade w/ CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Mydriasis w/ adrenaline (epinephrine). Increased hypoglycaemic effect of antidiabetic medicinal products.
ATC Classification
S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
DuoTrav eye drops
2.5 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in